Fluoxetine. A pharmacoeconomic review of its use in depression (Q33581956)

28 July 2017

1 reference

title

Fluoxetine. A pharmacoeconomic review of its use in depression (English)

1 reference

28 July 2017

Wilde MI

1

1 reference

28 July 2017

Benfield P

series ordinal

2

1 reference

28 July 2017

publication date

1 May 1998

1 reference

28 July 2017

1 reference

28 July 2017

volume

13

1 reference

28 July 2017

issue

5 Pt 1

1 reference

28 July 2017

page(s)

543-561

1 reference

The added costs of depression to medical care

28 July 2017

cites work

1 reference

12 December 2020

Lifetime risk of depression.

1 reference

12 December 2020

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline

1 reference

12 December 2020

Modelling the cost effectiveness of antidepressant treatment in primary care

1 reference

12 December 2020

The treatment of depression: prescribing patterns of antidepressants in primary care in the UK

1 reference

12 December 2020

Effectiveness and economic impact of antidepressant medications: a review.

1 reference

12 December 2020

Depression: a neglected major illness.

1 reference

12 December 2020

The SSRIs: advantages, disadvantages and differences

1 reference

12 December 2020

Fluoxetine: a five-year review

1 reference

12 December 2020

Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in The Netherlands: a multivariate analysis

1 reference

12 December 2020

Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline

1 reference

12 December 2020

Cost-effectiveness of antidepressant treatment reassessed

1 reference

12 December 2020

Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.

1 reference

12 December 2020

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness

1 reference

12 December 2020

Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland

1 reference

12 December 2020

Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

1 reference

12 December 2020

Pharmacoeconomic issues in the treatment of depression

1 reference

12 December 2020

Antidepressant dose patterns in Swedish clinical practice

1 reference

12 December 2020

Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis

1 reference

12 December 2020

A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients

1 reference

12 December 2020

Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis

1 reference

12 December 2020

Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

1 reference

12 December 2020

A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression.

1 reference

12 December 2020

The economic consequences of not treating depression

1 reference

12 December 2020

Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications

1 reference

12 December 2020

Fluoxetine vs. tricyclic antidepressants in women with major depressive disorder

1 reference

12 December 2020

Epidemiology of psychiatric disorders in Edmonton. Major depressive disorder.

1 reference

12 December 2020

Venlafaxine. A review of its pharmacology and therapeutic potential in depression

1 reference

12 December 2020

Selective serotonin reuptake inhibitor dose titration in the naturalistic setting.

1 reference

12 December 2020

Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.

1 reference

12 December 2020

A comparison of fluvoxamine and fluoxetine in the treatment of major depression

1 reference

12 December 2020

Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses

1 reference

12 December 2020

Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry

1 reference

12 December 2020

Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects

1 reference

12 December 2020

What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment

1 reference

12 December 2020

Are SSRIs a cost-effective alternative to tricyclics?

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

12 December 2020

Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

1 reference

12 December 2020

The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization

1 reference

12 December 2020

Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide

1 reference

12 December 2020

A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression

1 reference

12 December 2020

Selective serotonin reuptake inhibitors. Commercial interests should not influence prescribing.

1 reference

12 December 2020

Cost management: the economist's viewpoint.

1 reference

12 December 2020

Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system

1 reference

12 December 2020

The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population.

1 reference

12 December 2020

Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants.

1 reference

12 December 2020

Effect of antidepressant therapy on health care utilization and costs in primary care.

1 reference

12 December 2020

A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies

1 reference

12 December 2020

Predicting factors for absenteeism in patients with major depressive disorders.

1 reference

12 December 2020

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

1 reference

12 December 2020

Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice

1 reference

12 December 2020

Sex and depression in the National Comorbidity Survey. II: Cohort effects

1 reference

12 December 2020

Juggling cost and benefit in the long-term treatment of depression.

1 reference

12 December 2020

Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.

1 reference

12 December 2020

Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years

1 reference

12 December 2020

SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis

1 reference

12 December 2020

Health economic evaluations of antidepressants: a review

1 reference

12 December 2020

Pharmacotherapy of depressive disorders. A consensus statement. WHO Mental Health Collaborating Centres

1 reference

12 December 2020

Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology.

1 reference

12 December 2020

Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors.

1 reference

12 December 2020

Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France

1 reference

12 December 2020

The costs of depression.

1 reference

12 December 2020

Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults

1 reference

12 December 2020

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

1 reference

12 December 2020

Adequacy and duration of antidepressant treatment in primary care

1 reference

12 December 2020

Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine

1 reference

12 December 2020

Epidemiology of depression

1 reference

12 December 2020

Which antidepressant? A commentary from general practice on evidence-based medicine and health economics.

1 reference

12 December 2020

Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.

1 reference

12 December 2020

Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings

1 reference

12 December 2020

Economics of treatment of depression.

1 reference

12 December 2020

Debits and credits in the management of depression.

1 reference

12 December 2020

Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization

1 reference

12 December 2020

Sex differences in rates of depression: cross-national perspectives

1 reference

12 December 2020

A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness

1 reference

12 December 2020

SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study

1 reference

12 December 2020

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants

1 reference

12 December 2020

The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone

1 reference

12 December 2020

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis

1 reference

12 December 2020

Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders

1 reference

12 December 2020

Comparison of TCAs and SSRIs in the treatment of major depression in hospitalized geriatric patients

1 reference

12 December 2020

Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence

1 reference

12 December 2020

The costs of treating depression

1 reference

12 December 2020

Fluoxetine tenth anniversary update: the progress continues

1 reference

12 December 2020

Impact of fluoxetine on work loss in depression

1 reference

12 December 2020

Epidemiology of depression: prevalence, risk factors and treatment situation

1 reference

12 December 2020

Paroxetine. A pharmacoeconomic evaluation of its use in depression

1 reference

12 December 2020

Comparative tolerability profiles of the newer versus older antidepressants

1 reference

12 December 2020

Moclobemide. An update of its pharmacological properties and therapeutic use

1 reference

12 December 2020

Severity of depression and response to fluoxetine

1 reference

12 December 2020

Cost implications of initial antidepressant selection in primary care

1 reference

12 December 2020

Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy

1 reference

12 December 2020

Antidepressants and suicide

1 reference

12 December 2020

The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics

1 reference

12 December 2020

Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization.

1 reference

12 December 2020

The economic burden of depression in 1990.

1 reference

12 December 2020

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

12 December 2020

Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability

1 reference

12 December 2020

Reducing the economic burden of depression

1 reference

12 December 2020

Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions

1 reference

12 December 2020

The economic burden of depression.

1 reference

12 December 2020

Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population

1 reference

12 December 2020

The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression.

1 reference

12 December 2020

10.2165/00019053-199813050-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1049665197

0 references

1 reference